Drug: Temodar
Generic: Temozolomide
The company: Merck ($MRK)/Bayer
Patent expiration date: August 31, 2013
Estimated Global Sales 2012: $882 million

The scoop: Merck hopes to gain 6 drug approvals in the next 18 months, which include the potential insomnia treatment suvorexant and osteoporosis treatment odanacatib. And it's a good thing those applications are ready; both Temodar, a brain cancer treatment, and Maxalt, a migraine drug, fall off patent next year. Combine that with a 55% tumble in Singulair sales to $602 million (the drug began facing generic competition in August), and Merck is in need of new approvals to temper the blow. Merck did receive some uplifting news last October with regards to Temodar, when the U.S. Supreme Court upheld a ruling that allows the company to block Teva Pharmaceutical Industries ($TEVA) from selling its generic until 2013. Still, Merck's third-quarter sales came in just below Wall Street expectations. Temodar's estimated sales for this year amount to $882 million.

For more:
Merck plots FDA app as sleep drug aces new trial
Merck prevails in appeals court on Temodar patent


Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.